FMS Stock Recent News

Fresenius Medical Care (FMS) is rated a buy, with shares up 32.95% YoY and strong Q1 2025 results, showing 60% (YoY) net income growth. My valuation using a forward P/S ratio suggests FMS is undervalued by over 130%, with a projected share price of $62.06 by 2026. Compared to peers, FMS offers the highest potential upside and a superior 3.07% dividend yield, making it an attractive value play.

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Fresenius (FMS) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?

Explore the latest report on the global outpatient clinics market, analyzing trends, revenue, and forecasts from 2023 to 2029. This comprehensive study covers services, specialty, regional insights, and ESG impacts, featuring profiles of key players like Johns Hopkins and Mayo Clinic. Discover market dynamics and competitive landscape strategies. Explore the latest report on the global outpatient clinics market, analyzing trends, revenue, and forecasts from 2023 to 2029. This comprehensive study covers services, specialty, regional insights, and ESG impacts, featuring profiles of key players like Johns Hopkins and Mayo Clinic. Discover market dynamics and competitive landscape strategies.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.

Unlock your portfolio value by investing in stocks like FMS, EGO, HOPE and HRTG.

Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks?

High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States BAD HOMBURG, Germany , July 3, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, will extend High-Volume Hemodiafiltration (HighVolumeHDF) access for patients in seven out of 10 centers in Mexico, by partnering with the country's Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE) to develop a pilot program that provides low-income patients without medical coverage in Mexico with access to hemodialysis therapies.   Fresenius Medical Care Mexico and CCINSHAE signed a two-year contract to enable the installation of the Fre

Fresenius Medical Care unveils FME Reignite, targeting one billion euros in cost savings, tech upgrades and enhanced shareholder returns.

Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or RxSight, Inc. (RXST). But which of these two companies is the best option for those looking for undervalued stocks?